# SENTARA HEALTH PLANS

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

**Directions**: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

**The Sentara Health Plans Oncology Program is administered by OncoHealth**

- **For any oncology indications**, the most efficient way to submit a prior authorization request is through the **OncoHealth OneUM Provider Portal** at https://oneum.oncohealth.us. Fax to **1-800-264-6128.** OncoHealth can also be contacted by Phone: 1-888-916-2616.
- Commercial customers **NOT** enrolled in the OncoHealth program, please fax requests to Sentara Health plans at fax number 1-844-668-1550.

**Drug Requested**: **Gonadotropin-releasing Hormone Agonists (GnRH) (PHARMACY)**

| Preferred Drugs | | |
|---|---|---|
| ❑ **Eligard®** (leuprolide acetate) **7.5 mg (1-month)** | ❑ **Eligard®** (leuprolide acetate) **22.5 mg (3-month)** | ❑ **Eligard®** (leuprolide acetate) **30 mg (4-month)** |
| ❑ **Eligard®** (leuprolide acetate) **45 mg (6-month)** | ❑ **Leuprolide acetate 5 mg/mL SubQ Solution** | ❑ **Leuprolide Depot 22.5 mg (3-month) [vial]** |
| ❑ **Lupron Depot®** (leuprolide acetate) **3.75 mg (1-month)** | ❑ **Lupron Depot®** (leuprolide acetate) **7.5 mg (1-month)** | ❑ **Lupron Depot®** (leuprolide acetate) **11.25 mg (3-month)** |
| ❑ **Lupron Depot®** (leuprolide acetate) **22.5 mg (3-month) [syringe kit]** | ❑ **Lupron Depot®** (leuprolide acetate) **30 mg (4-month)** | ❑ **Lupron Depot®** (leuprolide acetate) **45 mg (6-month)** |
| ❑ **Lupron Depot-Ped®** (leuprolide acetate) **7.5 mg (1-month)** | ❑ **Lupron Depot-Ped®** (leuprolide acetate) **11.25 mg (1-month)** | ❑ **Lupron Depot-Ped®** (leuprolide acetate) **15 mg (1-month)** |
| ❑ **Lupron Depot-Ped®** (leuprolide acetate) **11.25 mg (3-month)** | ❑ **Lupron Depot-Ped®** (leuprolide acetate) **30 mg (3-month)** | ❑ **Lupron Depot-Ped®** (leuprolide acetate) **45 mg (6-month)** |
| ❑ **Lutrate Depot** (leuprolide acetate) **22.5 mg (3-month) [vial]** | ❑ **Trelstar®** (triptorelin pamoate) **3.75 mg (1-month)** | ❑ **Trelstar®** (triptorelin pamoate) **11.25 mg (3-month)** |
| ❑ **Trelstar®** (triptorelin pamoate) **22.5 mg (6-month)** | ❑ **Zoladex®** (goserelin) **3.6 mg (1-month)** | ❑ **Zoladex®** (goserelin) **10.8 mg (3-month)** |

**(Continued on next page)**

| Non-Preferred Drugs | | |
|---|---|---|
| ❑ **Fensolvi®** (leuprolide acetate) **45mg (6-month)** | ❑ **Supprelin® LA** (histrelin acetate) **50mg (12-month)** | ❑ **Synarel®** (nafarelin acetate) **2mg/ml** (*dosing of 1600 mcg to 1800 mcg per day more than the 400 mcg to 800 mcg per day for endometriosis) |
| ❑ **Triptodur®** (triptorelin) **22.5 mg (6-month)** | | |

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

**Member Name:** _____

**Member Sentara #:** _____ **Date of Birth:** _____

**Prescriber Name:** _____

**Prescriber Signature:** _____ **Date:** _____

**Office Contact Name:** _____

**Phone Number:** _____ **Fax Number:** _____

**NPI #:** _____

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

**Drug Name/Form/Strength:** _____

**Dosing Schedule**: _____ **Length of Therapy**: _____

**Diagnosis:** _____ **ICD Code, if applicable:** _____

**Weight (if applicable):** _____ **Date weight obtained:** _____

## A. Length of Authorization:

- Endometriosis: Coverage will be provided for 6 months and is eligible for conditional 12-month renewal
- Uterine leiomyomata (fibroids): Coverage will be provided for 6 months and is eligible for conditional 12-month renewal
- Gender Dysphoria & Disorders of Sex Development: Coverage will be provided for 12 months and may be renewed annually
- All other indications: Coverage will be provided for 12 months and may be renewed annually

**(Continued on next page)**

## B. Quantity Limits:

| Drug Name | Strength | Quantity | Day Supply |
|---|---|---|---|
| Leuprolide acetate SubQ solution | 5 mg/mL (1 mg/0.2 mL multi-dose vial) | 2 vials | 28 days |
| Leuprolide Depot 3-month | 22.5 mg | 1 vial | 84 days |
| Lupron Depot 1-month | 3.75 mg, 7.5 mg | 1 injection | 28 days |
| Lupron Depot 3-month | 11.25 mg, 22.5 mg | 1 injection/vial | 84 days |
| Lupron Depot 4-month | 30 mg | 1 injection | 112 days |
| Lupron Depot 6-month | 45 mg | 1 injection | 168 days |
| Lupron Depot-Ped 1-month | 7.5 mg, 11.25 mg, 15 mg | 1 injection | 28 days |
| Lupron Depot-Ped 3-month | 11.25 mg, 30 mg | 1 injection | 84 days |
| Lupron Depot-Ped 6-month | 45 mg | 1 injection | 168 days |
| Lutrate Depot 3-month | 22.5 mg | 1 vial | 84 days |
| Eligard 1-month | 7.5 mg | 1 injection | 28 days |
| Eligard 3-month | 22.5 mg | 1 injection | 84 days |
| Eligard 4-month | 30 mg | 1 injection | 112 days |
| Eligard 6-month | 45 mg | 1 injection | 168 days |
| Fensolvi 6-month | 45 mg | 1 injection | 168 days |
| Trelstar 1-month | 3.75 mg | 1 injection | 28 days |
| Trelstar 3-month | 11.25 mg | 1 injection | 84 days |
| Trelstar 6-month | 22.5 mg | 1 injection | 168 days |
| Triptodur 6-month | 22.5 mg | 1 injection | 168 days |
| Supprelin LA | 12-month | 1 implant | 365 days |
| Synarel | 2 mg/mL (200 mcg/spray) | 1 bottle (8 mL) | 28 days |
| Zoladex 1-month | 3.6 mg | 1 implant | 28 days |
| Zoladex 3-month | 10.8 mg | 1 implant | 84 days |

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

### ❑ Diagnosis: Gender Identity/Gender Dysphoria

**Initial Authorization**

❑ Member is 19 years of age or older and has a diagnosis of gender dysphoria

**(Continued on next page)**

**Note:** For FAMIS members, Gender Dysphoria Diagnosis is an **Excluded Benefit for members under 19** years of age.

In accordance with a new federal rule (2026-16508 (91 FR 52406), the Department of Medical Assistance Services (DMAS) will no longer cover gender-affirming procedures, including certain drugs/hormone therapies, to youth enrolled in Medicaid and the Children's Health Insurance Program (CHIP) beginning **October 13, 2026**. These restrictions also prohibit states' use of the federal Medicaid Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) pathway to provide coverage of these services to children under 18.

- ❑ Provider attests member has the capacity to make informed treatment decisions and has assented to treatment after discussion of the potential benefits and risks
- ❑ Member has been assessed and diagnosed with gender dysphoria according to DSM-V criteria, by **ONE** of the following provider types:
  - ❑ A licensed mental health provider
  - ❑ An endocrinologist
  - ❑ A gender dysphoria-informed hormone prescriber, defined as a provider competent in the assessment of gender dysphoria who practices in conjunction with a multidisciplinary gender dysphoria care team
- ❑ Medication is prescribed by, or in consultation with, a licensed mental health provider, endocrinologist or other medical provider experienced in gender dysphoria hormone therapy
- ❑ Provider attests coexisting behavioral health and medical comorbidities or social problems that may interfere with diagnostic procedures or treatment are being appropriately treated and are not causing symptoms of gender dysphoria
- ❑ Member has experienced puberty development to at least **ONE** of the following:
  - ❑ Tanner stage 2 (stage 2 through 4)
  - ❑ Lab values for Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH), and the endogenous sex hormones consistent with at least Tanner stage 2 **(must submit documentation)**
- ❑ If requesting a non-preferred drug, the member has failed **ONE** of the preferred formulations noted above

## ❑ Diagnosis: Disorders of Sex Development

### Initial Authorization

- ❑ Member has **ONE** of the following diagnoses for disorders of sex development **(must submit documentation)**:
  - ❑ Q56.0-Q56.4 (sex differentiation disorders)
  - ❑ Q97.x (Other sex chromosome abnormalities, female phenotype)
  - ❑ Q99.0 (46,XX/46,XY chimerism)
  - ❑ E25.X (Adrenogenital disorders)
  - ❑ E30.0-E30.9 (puberty disorders)
  - ❑ E34.5 (Androgen insensitivity syndrome)

**(Continued on next page)**

## ❑ Diagnosis: Central Precocious Puberty

**Initial Authorization**

- ❑ Member is less than 13 years of age
- ❑ Onset of secondary sexual characteristics associated with pubertal pituitary gonadotropin activation, occurring earlier than age 8 for girls and age 9 for boys **(submit documentation, progress notes, medical documentation recording physical changes, Tanner staging)**
- ❑ Diagnosis of central precocious puberty is confirmed by **ALL** of the following:
  - ❑ Laboratory documentation of pubertal gonadal sex steroid level
  - ❑ Pubertal luteinizing hormone response simulation by native GnRH **[Laboratory documentation demonstrating basal LH (>0.3 IU/L), and peak stimulated LH (>4-6 IU/L)]**
  - ❑ X-Ray results of the estimated bone age of the non-dominant wrist and hand greater than 2 standard deviations beyond chronological age **(submit laboratory and x-ray documentation)**
- ❑ A tumor has been ruled out by lab tests such as diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), and human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor)
- ❑ Medication will **NOT** be used in combination with growth hormone therapy
- ❑ The quantity (dose) requested is in accordance with FDA-approved labeling, and if applicable or necessary, age and weight conditions are met
- ❑ If requesting a non-preferred drug, the member has failed **ONE** of the preferred formulations noted above

## ❑ Diagnosis: Gynecological Indications

**Initial Authorization**

- ❑ Member is 18 years of age or older
- ❑ If requesting a non-preferred drug, the member has failed **ONE** of the preferred formulations noted above
- ❑ Treatment is being prescribed by or in consultation with a specialist in gynecology or reproductive health
- ❑ Select **ONE** of the following indications for use:
  - ❑ **FOR UTERINE LEIOMYOMATA, FIBROIDS** (requires chart notes documenting symptomology/pelvic exam, transvaginal ultrasonography, sono-hysterography):
    - ❑ Member is premenopausal
    - ❑ Member has uterine leiomyomas (fibroids)
    - ❑ Member is using for the management of heavy menstrual bleeding
    - ❑ Member does **NOT** have any contraindications to therapy including osteoporosis, history of thrombotic or thromboembolic disorders, uncontrolled hypertension, or hepatic impairment/disease

**(Continued on next page)**

- ❑ Member has history of inadequate response to the following therapies, tried for at least three (3) months each **(must submit chart note documentation of all therapy failures)**:
  - ❑ Oral contraceptives OR a selective progesterone receptor modulator OR intrauterine device
  - ❑ NSAIDs (non-steroidal anti-inflammatory drugs)
  - ❑ tranexamic acid 650 mg

    **OR**
  - ❑ Member has had surgery for uterine fibroids (i.e., ablation, myomectomy) and has persistent symptoms **(must submit documentation of date/type of surgery or procedure)**
- ❑ The quantity (dose) and administration frequency requested is in accordance with FDA-approved labeling, and if applicable or necessary, age and weight conditions are met

❑ **FOR ENDOMETRIOSIS** (requires chart notes detailing and recording treatment plan and/or symptomology of chronic pelvic pain (defined as noncyclical pain lasting 6 or more months that localizes to the anatomic pelvis, anterior abdominal wall at or below the umbilicus, the lumbosacral back, or the buttocks, and is of sufficient severity to cause functional disability or lead to medical care), amenorrhea, preoperative ablation treatment):

- ❑ Member is premenopausal
- ❑ Member has a diagnosis of moderate to severe pain associated with endometriosis
- ❑ Diagnosis of endometriosis has been confirmed by direct visualization during surgery and/or histology
- ❑ Member does **NOT** have any contraindications to therapy including osteoporosis, severe hepatic impairment/disease, or concomitant use of hormonal contraceptives
- ❑ Member has history of inadequate response to the following therapies, tried for at least three (3) months each **(must submit chart note documentation of all therapy failures)**:
  - ❑ NSAIDs (non-steroidal anti-inflammatory drugs
  - ❑ Combination (estrogen/progesterone) oral contraceptive
  - ❑ Progestins

    **OR**
  - ❑ Member has had surgical ablation to prevent recurrence
- ❑ The quantity (dose) and administration frequency requested is in accordance with FDA-approved labeling, and if applicable or necessary, age and weight conditions are met

**Reauthorization:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member continues to meet all initial criteria

**(Continued on next page)**

❑ **Diagnosis: Central Precocious Puberty** (Please submit chart notes and other supporting documents)

- ❑ Member is **NOT** over the age of 13
- ❑ Member has experienced disease response as indicated by lack of progression or stabilization of secondary sexual characteristics, decrease in growth velocity and bone age advancement, and improvement in final height prediction
- ❑ Member has experienced an absence of unacceptable toxicity from the drug (e.g., convulsions, development or worsening of psychiatric symptoms)

❑ **Diagnosis: Gynecological Indications** (Please submit chart notes and other supporting documents)

- ❑ Total duration of therapy (initial plus re-treatment for symptom recurrence) should not exceed 12 months, **AND** will be used in combination with add-back therapy, unless clinically contraindicated

**OR**

- ❑ The member's medical history and medical condition's current status requires longer treatment duration than otherwise recommended in published compendia/FDA labeling.

  Please provide an explanation along with any pertinent progress notes of medical condition including recorded recurrence of symptoms, procedure/exam results:

  _____

  _____

  _____

  _____

  _____

  _____

**AND**

- ❑ Prescriber will order and review a bone density assessment prior to re-treatment

**Medication being provided by Specialty Pharmacy – Proprium Rx**

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****



***Approved by Pharmacy and Therapeutics Committee**: ~~3/17/2022; 2/16/2023;~~ **5/22/2025**
**REVISED/UPDATED/REFORMATTED:** ~~5/4/2022; 6/21/2022; 3/9/2023; 2/28/2025; 4/24/2025;~~ **6/17/2025**